Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abiomed, Inc. Raises Low End Of Prior FY 2013 Revenue Guidance To A Range Above Analysts' Estimates


Thursday, 2 Aug 2012 07:00am EDT 

Abiomed, Inc. announced that based on current expectations, it is updating fiscal 2013 revenue guidance from the prior range of $152 million to $157 million to a revised range of $155 million to $157 million, representing annual growth of 23% to 24%, with worldwide Impella revenues forecast to grow greater than 30%. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $153 million for fiscal 2013. 

Company Quote

24.92
-0.05 -0.20%
11 Jul 2014